[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-dialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-dialysis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,67,93,122,147,168,195,216,237,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100494686","phase-4-icodextrin-postpones-the-shift-of-low-dose-to-full-dose-dialysis-in-the-first-year-of-incremental-peritoneal-dialysis-100494686",false,"NCT05721404","Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis","Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* The estimated glomerular filtration rate (eGFR) ≥ 3ml\u002Fmin·1.73m2 when enrolled;\n* The 24-hour urine volume ≥ 500ml when enrolled;\n* The patient or his lawful representative is able to receive and complete training of home peritoneal dialysis;\n* Patients were able to follow the follow-up schedule and other requirements of the study;\n* Patients can come to the peritoneal dialysis center for regular follow-up (once every 2 months or more);\n* Participants were expected to remain on peritoneal dialysis for at least 13 months;\n* Patients with good compliance;\n* Informed consent was obtained.\n\nExclusion Criteria:\n\n* Treated with both peritoneal dialysis and hemodialysis;\n* Patients who have previously received a kidney transplant and have been receiving immunosuppressive therapy;\n* Contraindications to bioelectrical impedance analysis (BIA) testing (e.g., amputation, use of a pacemaker or prosthesis);\n* Allergy to Icodextrin, starch and starch products, or suffer from glycogen storage disease;\n* Contraindications for the use of icodextrin;\n* HIV-positive participants;\n* Patients with tumors or other serious diseases have a life expectancy of less than one year;\n* Mental illness that interferes with the patient's understanding of the test requirements and completion of the test process;\n* Chronic wasting diseases such as tuberculosis, cirrhosis, hematological or other malignancies;\n* Patients who are pregnant, intending to become pregnant, or breastfeeding during the study period;\n* The patients had a history of drug abuse or alcoholism 2 years before the screening period;\n* Patients who are unwilling or not expected to fully comply with the visits and evaluations required by the protocol;\n* Patients who, in the investigator's judgment, have other serious or acute medical conditions that may prevent them from participating in the study.","ALL","18 Years",{"count":19,"type":20},194,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","We hypothesize incremental peritoneal dialysis (incremental PD) protocol with icodextrin solution will help patients to achieve adequate ultrafiltration and adequate dialysis with less glucose exposure by manipulating a low frequency of exchanges, therefore prolong the time from incremental protocol to full dose protocol (Full dose dialysis is defined as a dialysis dose of more than 8 L (4 exchanges of 2 L) per day). The goal of this clinical trial is to investigate the effect of icodextrin postponing the shift of low dose to full dose dialysis in the first year of incremental peritoneal dialysis. The main questions are:\n\n* The effect of icodextrin on the shift of low dose to full dose dialysis in the first year in patients on incremental peritoneal dialysis.\n* The effect of icodextrin on clinical outcomes in patients on incremental peritoneal dialysis, such as the first episode of peritonitis, the incidence of anuria, the first incidence of hospitalization, technical failure, all cause mortality, cardiovascular disease free survival and the quality of life.\n\nParticipants will be 1:1 randomized to the ICO (icodextrin) arm and CON (control) arm. Both arms patients will be followed every 2 months for fluid status by bioimpedance analysis. An extracellular water \u002Ftotal body water (ECW\u002FTBW) ≥ 0.40 or edema is defined as overhydration (OH). The OH patients in the ICO arm will be prescribed icodextrin (Extraneal) for long night dwell to improve fluid overload till their re-measurement of ECW\u002FTBW \\\u003C 0.40 or edema disappeared. The OH patients in the CON arm will be prescribed hypertonic Dextrose solution for long night dwell to improve fluid overload till their ECW\u002FTBW \\\u003C 0.40 or edema disappeared.\n\nResearchers will compare the time of transferring from low dose PD to full dose and the clinical outcomes in the first year between the patients in ICO and CON groups to see the effect of icodextrin on the shift of low dose to full dose dialysis and clinical outcomes in the first year in patients on incremental peritoneal dialysis. Successful completion of the study will advance our strategy of incremental PD and help to prolong the shift from incremental to full dose dialysis, and offer new opportunities for the development of an effective and economical therapy for PD patients with residual kidney function (RKF)",[26],"Peritoneal Dialysis",[28,29,30],"peritoneal dialysis","incremental peritoneal dialysis","icodextrin","RECRUITING","2026-06-26",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2023-05-24",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100641837","predicting-peritoneal-ktvurea-based-on-single-exchange-dialysate-effluent-100641837","NCT07659067","Predicting Peritoneal Kt\u002FVurea Based on Single-Exchange Dialysate Effluent","Development and Validation of a Prediction Model for Peritoneal Kt\u002FVurea Using Single-Exchange Dialysate Effluent in Patients Undergoing Peritoneal Dialysis","Inclusion Criteria:\n\nPatients aged ≥14 years who have been receiving PD for at least one month.\n\nExclusion Criteria:\n\n(1) peritonitis or other acute complications (e.g., severe infection or acute heart failure) within 1 month prior to enrollment; (2) spontaneous ascites; (3) inability to complete full collection of all dialysate effluent during the study dialysis day; (4) refusal or inability to provide written informed consent.","14 Years",{"count":53,"type":20},300,"OBSERVATIONAL","Background:\n\nPeritoneal dialysis (PD) adequacy is routinely evaluated using the urea clearance index (Kt\u002FVurea), a key indicator of small-solute clearance and treatment adequacy. The standard method for calculating peritoneal Kt\u002FVurea requires complete collection of 24-hour dialysate effluent, which is labor-intensive, time-consuming, and prone to errors arising from incomplete collection, inadequate mixing, and inaccurate sampling. Although proportional sampling from each exchange has been shown to yield results comparable to those obtained from complete 24-hour effluent collection, this approach still requires collection of all exchanges throughout the day. Previous studies have suggested that Kt\u002FVurea estimated from a single dialysate exchange may correlate with the standard measurement; however, these investigations were limited by small sample sizes and did not establish predictive equations. Therefore, a practical and accurate alternative for assessing peritoneal Kt\u002FVurea is still lacking.\n\nObjective:\n\nTo develop and validate a prediction model for peritoneal Kt\u002FVurea based on single-exchange dialysate effluent in patients undergoing PD.\n\nMethods:\n\nThis multicenter cross-sectional study will be conducted between 2026 and 2027 across four PD centers in China. Consecutive prevalent patients receiving manual PD will be screened for eligibility. Patients aged ≥14 years who have been receiving PD for at least one month will be included. Exclusion criteria comprise peritonitis or other acute complications within the preceding month, spontaneous ascites, inability to complete full dialysate collection during the study day, and refusal to provide informed consent. Demographic characteristics, primary kidney disease, comorbidities, and PD prescription parameters will be collected. On a designated study day, effluent from each dialysis exchange, 24-hour urine samples, and fasting blood samples will be obtained. The correlations between peritoneal Kt\u002FVurea calculated from individual exchanges and the reference peritoneal Kt\u002FVurea derived from complete 24-hour dialysate collection will be evaluated. Multivariable prediction models incorporating single-exchange effluent measurements and relevant clinical parameters will subsequently be developed and validated. Model performance will be assessed using measures of discrimination, calibration, and agreement with reference Kt\u002FVurea values.\n\nConclusions:\n\nThis study aims to establish and validate a simplified method for estimating peritoneal Kt\u002FVurea using single-exchange dialysate effluent. If validated, the proposed model may substantially reduce the burden associated with 24-hour dialysate collection while maintaining adequate accuracy for routine assessment of PD adequacy.",[26],"NOT_YET_RECRUITING","2026-06-16",{"date":60,"type":35},"2026-06-22",{"date":62,"type":20},"2026-06",{"date":64,"type":20},"2027-06",{"name":66,"class":42},"Peking University First Hospital",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":43},"100584049","phase-3-comparing-high-and-low-dose-iron-treatments-for-people-on-peritoneal-dialysis-the-paladin-study-100584049","NCT06884280","Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study","Proactive High Dose Versus Low-dose Reactive Intravenous or Oral Iron in People on Peritoneal Dialysis (PALaDIN) - an Open-label, Feasibility Randomised Study","PALaDIN","Inclusion Criteria:\n\n* Males and females aged ≥18 years.\n* Able to give informed consent\n* Serum ferritin \\\u003C700ug\u002FL\n* Transferrin saturation level \\\u003C40%\n* No intravenous iron for last 4 weeks before randomisation (patients may be pre-identified and included after 4-week washout period)\n* Received maintenance peritoneal dialysis therapy for at least 4 weeks\n* Expected to remain on peritoneal dialysis therapy for duration of study\n\nExclusion Criteria:\n\n* Inadequate dialysis deemed by responsible clinician\n* Probability of need for transfusion within 1 week of enrolment\n* On or received a HIF-PHI in the past 4 weeks\n* Anticipated major surgery that the responsible clinician feels will impact response to treatment\n* Haemochromatosis \u002F haemosiderosis or ALT \\>x3 normal\n* Are deemed to be most suited to best-supportive or end-of-life care at time of screening\n* Women of childbearing potential not using effective means of contraception\n* Have been involved in another medicinal study (CTIMP) within past 4 weeks\n* Known allergy or adverse reaction to oral or intravenous iron preparations\n* CRP \\>50, TSATs \\>40%, SF \\>700 at time of recruitment\n* Active infection, HIV, active Hep B or C\n* Are unable or unwilling to consent to or complete the study procedures",{"count":76,"type":20},30,[78],"PHASE3","Chronic kidney disease affects a significant portion of the UK population, with approximately 3.5 million adults diagnosed. At its most severe stage, end-stage kidney disease, individuals require frequent dialysis treatment. One form of dialysis, known as peritoneal dialysis, involves introducing and removing fluid from the abdominal cavity to help filter out toxins from the body.\n\nThe kidneys are involved in various hormonal processes, including those responsible for producing red blood cells, making anaemia a common consequence of kidney failure. When designing a clinical trial to evaluate the effectiveness of any treatment, it is essential to determine the number of suitable and willing participants, as well as those who can complete all required tests and measurements. Identifying the most appropriate measurement to assess the impact of intravenous iron (iron injected directly into veins) is crucial to ensure that any observed changes are meaningful to people with CKD and their carers. To address these considerations, the investigators will conduct a pilot feasibility trial.\n\nIn this trial, individuals with kidney disease undergoing peritoneal dialysis will be randomly assigned to receive either high-dose or low-dose intravenous iron, or oral iron therapy. Over twelve months, the investigators will monitor their anaemia response, symptoms of kidney disease, quality of life, physical performance (such as the ability to walk for six minutes), and cognitive function. Additionally, the investigators will assess the impact of each intervention on the frequency of blood transfusions, whether those on oral iron require intravenous iron, and any changes in the dosage of erythropoietin-stimulating agents (drugs that increase blood production).",[26,81,82],"Anaemia","Iron Deficiency, Anaemia","2026-05-05",{"date":85,"type":35},"2026-05-06",{"date":87,"type":35},"2025-11-13",{"date":89,"type":20},"2027-10",{"name":91,"class":92},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100619956","phase-4-bisacodyl-oral-for-lowering-dysfunction-of-tenckhoff-catheter-100619956","NCT07351357","Bisacodyl Oral for Lowering Dysfunction (of Tenckhoff Catheter)","Multi-Centre Pragmatic Randomized Controlled Trial of Bowel Preparation Before Peritoneal Dialysis Catheter Insertion","BOLD","Inclusion Criteria:\n\n* aged 18 or older and need of peritoneal dialysis\n* willingness to give written consent and comply with the study protocol\n\nExclusion Criteria:\n\n* known contraindication to peritoneal dialysis\n* ongoing diarrhoea or active inflammatory bowel disease\n* participation in another interventional study within last 30 days of randomization\n* history of a psychological illness or condition that would interfere with the patient's ability to understand the requirement of the study and\u002For comply with the dialysis procedures",{"count":102,"type":20},398,[23],"Doctors need to insert catheter for patients who are going to have peritoneal dialysis. These peritoneal catheters can be obstructed or blocked afterward. The chance of not having smooth flow can be up to 12 and 31%. So far, constipation is one of the proposed reasons. Therefore, the study is aimed to investigate whether the preventive use of laxative before the surgery can help better improve the function of the catheter and hence better flow.",[106,26],"Renal Failure Chronic Requiring Dialysis",[28,108,109,110,111],"Tenckhoff catheter","laxative","bowel preparation","catheter dysfunction","2026-01-17",{"date":114,"type":35},"2026-01-21",{"date":116,"type":20},"2026-01-12",{"date":118,"type":20},"2027-09-30",{"name":120,"class":42},"Chinese University of Hong Kong",6,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":43},"100613809","phase-4-blood-pressure-control-with-thiazide-diuretics-in-peritoneal-dialysis-patients-100613809","NCT07271420","Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients","Inclusion Criteria:\n\n* Patients on chronic peritoneal dialysis, with uncontrolled hypertension (SBP \\>140 mmHg and\u002For DBP \\>90 mmHg)\n\nExclusion Criteria:\n\n* Patients with a life expectancy of less than 3 months, planned conversion to hemodialysis, or scheduled kidney transplantation within 3 months",{"count":129,"type":20},40,[23],"To evaluate the blood pressure lowering effects of thiazide diuretics in patients on peritoneal dialysis",[133,26,134],"Hypertension","End Stage Kidney Disease (ESRD)",[133,136,137,138],"Thiazides diuretics","End stage kidney disease","Peritoneal dialysis","2025-11-26",{"date":141,"type":35},"2025-12-09",{"date":143,"type":35},"2020-01-01",{"date":145,"type":20},"2027-06-30",{"name":120,"class":42},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":43},"100608973","multi-omics-study-of-peritoneal-dialysis-effluent-to-explore-biomarkers-of-peritoneal-fibrosis-100608973","NCT07208513","Multi-omics Study of Peritoneal Dialysis Effluent to Explore Biomarkers of Peritoneal Fibrosis","Inclusion Criteria:\n\n1. Patients on peritoneal dialysis: a. Age 18-75 years; b. Regular abdominal dialysis due to uremia\\> 3 months; c. Signed informed consent\n2. Hemodialysis patients: a. Age 18-75 years; b. Due to regular hemodialysis due to uremia\\> 3 months old, allogeneic kidney transplantation is planned; c. Signed informed consent\n3. Patients with normal renal function: a. Age 18-75 years; b. Proposed elective inguinal hernia repair surgery; c. Signed informed consent.\n\nExclusion Criteria:\n\n1. Patients on peritoneal dialysis: a. History of peritonitis in the past 3 months; b. History of abdominal tumors with peritoneal metastases\n2. Hemodialysis patients: a. Previous abdominal dialysis history; b. History of abdominal tumors with peritoneal metastases Patients with normal renal function: a. History of chronic kidney disease; b. History of abdominal tumors with peritoneal metastases","75 Years",{"count":155,"type":20},55,"Biomarkers of peritoneal fibrosis in patients with peritoneal dialysis were investigated by transcriptomics of exfoliated cells and metabolomics of exfoliated cells in peritoneal dialysis",[26,158],"Peritoneal Fibrosis","2025-09-28",{"date":161,"type":35},"2025-10-06",{"date":163,"type":20},"2025-10-20",{"date":165,"type":20},"2026-09-30",{"name":167,"class":42},"Shanghai Jiao Tong University School of Medicine",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":43},"100600504","efficacy-and-safety-of-nalfurafine-hydrochloride-odt-for-moderate-to-severe-pruritus-in-patients-on-peritoneal-dialysis-100600504","NCT07098351","Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis","A Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Moderate to Severe Pruritus in Peritoneal Dialysis Patients","KARE-PD","Inclusion Criteria:\n\nAt the time of signing informed consent:\n\n* Aged 18-85 years (inclusive), regardless of gender.\n* Chronic renal failure patients on regular peritoneal dialysis for ≥3 months, with no anticipated major treatment changes or rapid disease progression during the trial.\n* Able to understand and comply with study procedures, voluntarily participate, and provide written informed consent.\n\nAt formal enrollment:\n\n* During the baseline period, ≥5 days with both morning and evening VAS scores recorded, and the average of the higher VAS values (morning\u002Fevening) ≥50 mm.\n* During the baseline period, ≥5 days with Xie-Kawashima itching severity assessed both morning and evening, including ≥2 days where the maximum itching score (morning\u002Fevening) was ≥3 (moderate).\n\nExclusion Criteria:\n\n* Poor dialysis compliance, deemed by the investigator to affect efficacy\u002Fsafety assessments.\n* Poor dialysis compliance, deemed by the investigator to affect efficacy\u002Fsafety assessments.\n* Peritoneal dialysis regimen adjusted within 2 weeks prior to screening.\n* Currently on or planning hemodialysis within 2 months.\n* Planned kidney transplant or elective surgery during the study.\n* Peritonitis within 4 weeks prior to screening, unable to continue peritoneal dialysis.\n* ALT, AST, GGT, or total bilirubin \\>2× upper limit of normal (ULN) during screening.\n* Pruritus not caused by chronic kidney disease (e.g., allergic, physical, infectious skin diseases, cholestatic liver disease).\n* Severe cardiovascular disease (NYHA Class III\u002FIV, acute MI, unstable angina, large pericardial effusion, severe arrhythmia, or ECG abnormalities deemed unsafe for participation).\n* Active malignancy within 12 months prior to screening, or recent radiotherapy\u002Fchemotherapy\u002Ftargeted\u002Fimmunotherapy.\n* Uncontrolled or drug-treated fungal\u002Fbacterial\u002Fviral infections (e.g., active TB, HIV).\n* Uncontrolled hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg).\n* Current systemic corticosteroids\u002Fimmunosuppressants (topical excluded).\n* Psychiatric or cognitive disorders.\n* Initiated\u002Fadjusted restricted medications (antihistamines, systemic\u002Flocal corticosteroids \\[excluding ear\u002Feye\\], calcineurin inhibitors, gabapentin, pregabalin) within 7 days prior to screening, or anticipated changes during the study.\n* Initiated\u002Fadjusted medications affecting pruritus assessment (antipsychotics, hypnotics, SSRIs, anxiolytics, TCAs) within 2 weeks prior to screening, or anticipated changes during the study.\n* Opioid agonists\u002Fantagonists used within 2 weeks prior to screening.\n* Phototherapy for pruritus within 1 month prior to screening.\n* History of drug abuse, dependence, or alcoholism within 12 months prior to screening.\n* Allergy to opioids or trial drug excipients.\n* Participation in another clinical trial with investigational drugs\u002Fdevices within 28 days prior to screening, or residual investigational drug within 5 half-lives.\n* Pregnant, breastfeeding, positive pregnancy test, or unwilling to use contraception during the study.\n* Other conditions deemed unsuitable by the investigator.","85 Years",{"count":178,"type":20},93,[180],"NA","Moderate to severe pruritus significantly impairs the quality of life in peritoneal dialysis patients, and effective treatment options remain limited. κ-opioid receptor agonists may alleviate itching by modulating neural signaling pathways. This study is a multicenter, prospective, single-arm clinical trial, planning to enroll 93 patients. It aims to test the hypothesis that nalfurafine hydrochloride orally disintegrating tablets compared to baseline, with acceptable safety.",[183,26,184,185],"Adverse Event","Moderate-to-severe Pruritus","Chronic Kidney Disease-associated Itch","2025-08-26",{"date":188,"type":35},"2025-09-03",{"date":190,"type":35},"2025-08-07",{"date":192,"type":20},"2026-06-30",{"name":194,"class":42},"Guangdong Provincial People's Hospital",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":43},"100598903","clinical-study-of-the-use-of-amino-acid-peritoneal-dialysate-in-diabetic-patients-100598903","NCT07077538","Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients","A Single Center, Open, Prospective, Self-control Clinical Study on the Use of Amino Acid Peritoneal Dialysis Fluid in Diabetes Patients","Inclusion Criteria:\n\n* Type I or II diabetes patients aged 18 to 75 years (including 18 and 75 years), regardless of gender;\n* Stable peritoneal dialysis patients who have undergone peritoneal dialysis treatment for ≥ 3 months;\n* Use 3-5 bags of peritoneal dialysis solution daily;\n* 6.0%\\\u003Cglycated hemoglobin (HbA1c) level ≤ 8.5%;\n* 90g\u002FL ≤ Hemoglobin concentration ≤ 130g\u002FL\n* Stable use of erythropoietin and rosuvastatin;\n* The fluctuation of carbohydrate energy supply ratio in the first 3 months before enrollment is less than 15%;\n* Not using amino acid (15) peritoneal dialysis solution for the first 3 months before enrollment;\n* Within the past month, the patient's prescription for hypoglycemic drugs has not been adjusted;\n* Within the past month, the patient's dietary structure and food intake have remained stable.\n\nExclusion Criteria:\n\n* Peritonitis has occurred within the past 3 months;\n* Use Acodextrin peritoneal dialysis solution;\n* Contraindications for the presence of amino acids (15) in peritoneal dialysis fluid:\n\n  1. Individuals allergic to any component of amino acid (15) peritoneal dialysis fluid;\n  2. Serum urea level\\>38 mmol\u002Fl;\n  3. Metabolic acidosis (CO2 binding capacity\\\u003C22mmol\u002FL);\n  4. Severe hypokalemia (blood potassium\\\u003C2.5mmol\u002FL);\n  5. Various congenital amino acid metabolism abnormalities;\n  6. Liver dysfunction (alanine aminotransferase levels exceeding 2.5 times the upper limit of normal);\n* Combined hemoglobinopathies: such as thalassemia, sickle cell disease, etc;\n* It is expected that kidney transplantation may be accepted during the trial period;\n* Participated in other clinical studies.",{"count":203,"type":20},70,[180],"The study is a single center, open, prospective, self controlled clinical study. The patients with diabetes who are to be enrolled in peritoneal dialysis are to observe the changes of glycosylated hemoglobin relative to the baseline 90 days after using amino acid (15) peritoneal dialysis solution.",[26,207],"Diabetes","2025-07-20",{"date":210,"type":35},"2025-07-22",{"date":212,"type":20},"2025-07-30",{"date":192,"type":20},{"name":215,"class":42},"The People's Hospital of Gaozhou",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":43},"100583489","the-mobile-based-training-system-in-peritoneal-dialysis-patients-100583489","NCT06876987","The Mobile-based Training System in Peritoneal Dialysis Patients","The Development and Evidence Effect of a Mobile-based Situational Simulation Peritoneal Dialysis Training System in the Retraining Program of Peritoneal Dialysis Patients","Inclusion Criteria:\n\n* Patients who have received peritoneal dialysis for more than 3 months; patients who have received peritoneal dialysis for less than 3 months but have recovered from peritonitis or catheter-related infection; patients who are conscious and have no mental illness.\n\nExclusion Criteria:\n\n* Patients who are unable to perform peritoneal dialysis independently; illiterate; suffering from peritonitis or catheter exit site infection.",{"count":224,"type":20},50,[180],"The mobile-based training system can effectively improve the knowledge and technical correctness of peritoneal dialysis patients.",[26],"2025-03-13",{"date":230,"type":35},"2025-03-14",{"date":232,"type":35},"2025-03-06",{"date":234,"type":20},"2026-03-05",{"name":236,"class":42},"China Medical University Hospital",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":21,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":43},"100558548","pharmacokinetics-of-single--and-double-dose-icodextrin-100558548","NCT06552546","Pharmacokinetics of Single- and Double-dose Icodextrin","Pharmacokinetics of Single- and Double-dose Icodextrin in Patients on Peritoneal Dialysis","Inclusion Criteria:\n\n* Patients with end stage renal disease, receiving peritoneal dialysis for \\> 3 months, and clinically stable.\n* Suitable for 4 exchanges of manual peritoneal dialysis on the first study day.\n\nExclusion Criteria:\n\n* History of allergic reaction to icodextrin dialysis solution or corn starch;\n* With malignant tumor receiving radiotherapy and\u002For chemotherapy, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, or HIV\u002FAIDS;\n* Acute systemic infection, peritonitis, catheter-related infection, cardiovascular disease, surgery, or trauma in the previous one month;\n* A high probability of receiving a kidney transplant or transferring to hemodialysis or drop-out due to socioeconomic causes within 1 months;\n* Receiving hybrid dialysis (peritoneal dialysis combined with hemodialysis);\n* Pregnant or lactating female;\n* Having used icodextrin within previous 30 days；\n* Peritoneal catheter dysfunction；\n* Not suitable for enrollment assessed by researchers, including those unable followed the study protocol, or enrolled in other intervention studies, or with other reasons considering not suitable for enrollment by researchers.","79 Years",{"count":246,"type":20},16,[180],"The study aims to provide the pharmacokinetics profiles of single- and double-dose icodextrin in patients on peritoneal dialysis (PD). It may expand the available knowledge of the clinical pharmacology of icodextrin following its intraperitoneal administration and fills the gaps in our understanding of the fate of icodextrin and the metabolic consequences of icodextrin and its metabolites.",[26],[251,252,138],"Icodextrin","Pharmacokinetics","2024-08-10",{"date":255,"type":35},"2024-08-14",{"date":257,"type":20},"2024-08-15",{"date":259,"type":20},"2025-03-30",{"name":66,"class":42},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":21,"phases":271,"briefSummary":272,"conditions":273,"keywords":277,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":43},"100322642","phase-3-alirocumab-in-patients-on-a-stable-dialysis-regimen-100322642","NCT03480568","Alirocumab in Patients on a Stable Dialysis Regimen","A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study","Inclusion Criteria:\n\n1. Male or female patients, ages 18 to 80 years.\n2. Written informed consent will be obtained before any study assessment is performed.\n3. Diagnosis of end-stage renal disease, maintained on dialysis, without dialysis complications, for at least 3 months.\n4. Patients may or may not have a diagnosis of atherosclerotic disease, such as a history of myocardial infarction (MI), cardiac percutaneous coronary intervention (PCI), coronary artery bypass (CABG) surgery, atherosclerotic transient ischemic attack (TIA) or cerebrovascular attack (CVA), or peripheral arterial disease (PAD).\n5. A total of 20 patients will be enrolled, 10 patients on hemodialysis and 10 patients on peritoneal dialysis.\n\nExclusion Criteria:\n\n1. LDL-cholesterol level of \\\u003C 70 mg\u002FdL.\n2. Any contraindication to subcutaneous injections.\n3. Patients on statin and\u002For ezetimibe therapy will have their cholesterol-lowering therapy continued as is without change during the time of the study.\n4. History of any allergy or intolerance to the study drug or drugs of the same class.\n5. A history of MI, PCI, CABG surgery, TIA, CVA, or PAD events within 3 months of enrollment.\n6. History of malignant cancer within the past 3 years, excepting basal cell skin cancer or cervical cancer in situ.\n7. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of the drug and for 2 weeks after the last injection of the drug. Highly effective methods of contraception include:\n\n   1. Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n   2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment.\n   3. Male sterilization (at least 6 months prior to enrollment). For female patients in the study, the vasectomized male partner should be the sole partner for that patient.\n   4. Use of oral (estrogen and\u002For progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C 1%), for example hormone vaginal ring or transdermal hormone contraception.\n   5. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment.\n   6. Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before enrollment.\n8. Pregnant or lactating women.\n9. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or extraction of study drug, at investigator's discretion.\n10. History or evidence of drug or alcohol abuse within the last 12 months.\n11. Patients considered unsuitable for the study, including patients with psychiatric, behavioral or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.","80 Years",{"count":270,"type":20},20,[78],"12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. Safety events will be obtained throughout the study.",[274,26,275,276],"Hemodialysis","Hypercholesterolemia","Atherosclerotic Disease",[278],"Alirocumab","2020-02-10",{"date":281,"type":35},"2020-02-12",{"date":283,"type":35},"2018-05-01",{"date":285,"type":20},"2020-12-31",{"name":287,"class":42},"Baylor Research Institute"]